Cargando…
Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone
BACKGROUND: Canine cutaneous mast cell tumor (MCT) is a common neoplastic disease associated with a variable biologic behavior. Surgery remains the primary treatment for canine MCT; however, radiation therapy (RT) and chemotherapy are commonly used to treat aggressive MCT. The goals of this study we...
Autores principales: | Webster, Joshua D, Yuzbasiyan-Gurkan, Vilma, Thamm, Douglas H, Hamilton, Elizabeth, Kiupel, Matti |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2529280/ https://www.ncbi.nlm.nih.gov/pubmed/18700956 http://dx.doi.org/10.1186/1746-6148-4-32 |
Ejemplares similares
-
Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors
por: Webster, Joshua D, et al.
Publicado: (2006) -
Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11
por: Gregory-Bryson, Emmalena, et al.
Publicado: (2010) -
c‐Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine
por: Weishaar, K.M., et al.
Publicado: (2017) -
A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies
por: Takada, Marilia, et al.
Publicado: (2018) -
Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone
por: Macedo, Thais Rodrigues, et al.
Publicado: (2022)